Anshuman Das, MD
Interventional Cardiology · Valparaiso, INNPI 1518255124
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,124 of the $19,247 with a category attached, or 63.0%. 23 manufacturers reported payments, led by Edwards Lifesciences at 29.8% of the total. 2025 is the largest year on record at $7,241, 4.7 times the $1,548 reported in 2019.
Across 317 payments — averaging $60.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$6K
- Boston Scientific$4K
- Abbott$4K
- Medtronic$3K
- Abiomed$826
- Shockwave Medical, Inc$543
- plus $1K from 17 others
What the payments were for
- Travel & lodging$7,12437%
- Food & beverage$12,12463%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 81 | $5,733 |
| Boston Scientific | 46 | $4,036 |
| Abbott | 55 | $3,681 |
| Medtronic(2 entities) | 36 | $3,001 |
| Abiomed | 17 | $826 |
| Shockwave Medical, Inc | 9 | $543 |
| Novartis | 17 | $303 |
| Amgen | 8 | $290 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $186 |
| Johnson & Johnson | 11 | $178 |
| Teleflex LLC | 2 | $97 |
| Cardiovascular Systems Inc. | 3 | $73 |
| Medical Device Business Services, Inc. | 2 | $59 |
| Boehringer Ingelheim | 3 | $49 |
| Merck | 3 | $44 |
| Angiodynamics, Inc. | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Bard Peripheral Vascular, Inc. | 1 | $18 |
| W. L. Gore & Associates, Inc. | 1 | $14 |
| Gilead | 1 | $14 |
| Amryt Pharma Holdings Ltd | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$2,021
- COREVALVE EVOLUT R$1,716
- Watchman$988
- SAPIEN 3 Ultra RESILIA$978
- GENERAL VASCULAR ACCESS$961
- Edwards SAPIEN 3 Transcatheter Heart Valve$733
- WATCHMAN Access System$728
- Impella$427
- CARDIOMEMS$311
- MitraClip System$287
- HeartMate 3 Left Ventricular Assist Device$140
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$136
- STINGRAY$125
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$124
- CoreValve Evolut$105
- PASCAL$104
- GENERAL - STRUCTURAL HEART$102
How this compares
$19,247 in reported general payments places this provider in the 80th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 123 | $147,578 |
| EntrestoSacubitril/Valsartan | 64 | $82,614 |
| BrilintaTicagrelor | 61 | $58,565 |
| JardianceEmpagliflozin | 31 | $40,293 |
| Repatha SureclickEvolocumab | 34 | $39,730 |
| XareltoRivaroxaban | 29 | $36,996 |
| Ranolazine ErRanolazine | 33 | $7,830 |
| Prasugrel Hcl | 54 | $7,742 |
| Metoprolol Succinate | 283 | $3,260 |
| ClopidogrelClopidogrel Bisulfate | 333 | $3,221 |
| Atorvastatin Calcium | 350 | $3,042 |
| Ezetimibe | 48 | $2,153 |
| Rosuvastatin Calcium | 112 | $1,329 |
| Amiodarone Hcl | 34 | $1,046 |
| Losartan Potassium | 115 | $990 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $303 | $82,61464 claims |
| Boehringer IngelheimJardiance | $49 | $40,29331 claims |
| Johnson & JohnsonXarelto | $178 | $36,99629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in Valparaiso
- Keith AtassiValparaiso$33K
- Sandeep SehgalValparaiso$22K
- Samer AbbasEast Chicago$395K
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Muzammil MusaniFort Wayne$184K
- Dean FerreraEast Chicago$180K
- Shashidhar DivakaruniMunster$97K
- Jarrod FrizzellEvansville$86K
- Navneet LatherNoblesville$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.